Delivery Order SPE2DB20D3103-SPE2DB25FP8Y5
Award Date 8/14/25
Potential Completion Date 8/15/25
Potential Value $9.8K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,652.96 to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials. This non-competitive, firm fixed-price delivery order was executed on October 28, 2025, with an ultimate completion date of October 29, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $13,014.23 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials on May 12, 2025, with a completion date of May 13, 2025. This firm fixed-price delivery order, issued without a set-aside designation, will be performed at the contractor's location in Conshohocken, Pennsylvania. Ruxience is a biosimilar medication used in oncology and immunology treatments, reflecting the agency's ongoing need to supply critical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 mL vials, valued at $13,824.28 under a firm fixed-price arrangement. This non-set-aside delivery order was awarded on July 8, 2025, with an ultimate completion date of July 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar monoclonal antibody used in the treatment of various cancers and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer treatment. This firm fixed-price delivery order, valued at $7,421.74, represents a non-set-aside competitive award with an ultimate completion date of August 13, 2025. The pharmaceutical products will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Ruxience 500 mg/50 ml vials valued at $5,969.24 under a firm fixed-price contract type. Ruxience is a biosimilar to rituximab, used in treating various cancers and autoimmune conditions. The delivery order carries an ultimate completion date of August 11, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania headquarters. This award represents a...
- The Defense Logistics Agency awarded a $39,673.94 delivery order to AmerisourceBergen Drug Corp for the supply of Ruxience 500 mg/50 ml vials on August 29, 2025, with an ultimate completion date of September 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $25,262.82 delivery order for Ruxience 500 mg/50 mL vials on September 25, 2025, with completion targeted for September 26, 2025. This firm fixed-price contract represents a non-competed award under an existing vehicle and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Ruxience is a biosimilar to rituximab used in the treatment of various cancers and autoimmune conditions, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $8,818.09 to AmerisourceBergen Drug Corp for Ruxience 500 mg/50 mL vials, a biosimilar medication used in cancer and immunological disorder treatment. This firm fixed price delivery order was issued on October 30, 2025, with an ultimate completion date of October 31, 2025, and represents a non-set-aside competitive award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ruxience 100 mg/10 mL vials valued at $1,956.80 under a firm fixed-price contract. This delivery order represents a non-set-aside competitive award and is part of a larger indefinite delivery contract (IDC) vehicle designated SPE2DX with the DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be performed and delivered...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Ruxience 500 mg/50 ml vials, a biosimilar medication used in cancer treatment and other therapeutic applications. This $5,073.74 firm fixed-price delivery order, with a completion date of November 5, 2025, represents a routine pharmaceutical procurement executed under a competitive, non-set-aside process. The award is issued under AmerisourceBergen's larger Indefinite...